Candel Therapeutics, Inc. CADL Free cash flow yield
Free cash flow yield at other companies
Other financials
Where this comes from
Calculated from Candel Therapeutics, Inc.’s reported figures.
Based on trailing twelve months.
The official record: Candel Therapeutics, Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Candel Therapeutics, Inc.'s free cash flow yield.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Candel Therapeutics, Inc.'s free cash flow yield?
- Candel Therapeutics, Inc. (CADL) reported free cash flow yield of -13.6% in Q1 2026.
- How has Candel Therapeutics, Inc.'s free cash flow yield changed year-over-year?
- Candel Therapeutics, Inc.'s free cash flow yield decreased by 33.9% year-over-year, from -10.2% to -13.6%.
- What is the long-term trend for Candel Therapeutics, Inc.'s free cash flow yield?
- Over 4 years (2021 to 2025), Candel Therapeutics, Inc.'s free cash flow yield has grown at a 4.0% compound annual growth rate (CAGR), from -10.7% to -12.5%.
- What does free cash flow yield mean?
- Trailing-twelve-month free cash flow divided by market capitalization at the quarter end. The cash return the business generates relative to its market price.